Clinical Trial: Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Gene Therapy (SPVN20) in Subjects With Rod-Cone Dystrophy

U.S., Sept. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07807111) titled 'Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Gene Therapy (SPVN20) in Subjects With Rod-Cone Dystrophy' on Aug. 10.

Brief Summary: This open-label, multi-center study is to evaluate the safety, tolerability, and efficacy of escalating doses of a gene therapy called SPVN20 administered via a single intravitreal injection in participants with advanced Rod-Cone Dystrophy.

Study Start Date: Oct. 08, 2025

Study Type: INTERVENTIONAL

Condition: Retinitis Pigmentosa (RP) Rod Cone Dystrophy

Intervention: BIOLOGICAL: SPVN20 (high dose)

SPVN20

BIOLOGICAL: SPVN20 (medium dose)

SPVN20

BIOLOGICAL: SPVN20 (low d...